Today, the American Kidney Fund (AKF) announces its 2025 Class of Corporate Members who serve as strategic partners in AKF’s Corporate Membership Program. Corporate Members provide vital support to ...

Verastem Oncology (NASDAQ:VSTM) announced on Wednesday that the U.S. FDA has cleared the investigational new drug application ...

Groundbreaking longevity research initiative brings together leading scientists and institutions to decode the genetic basis ...

Protagonist Therapeutics, Inc. (”Protagonist” or the “Company”) announced that an abstract was accepted for presentation at the Plenary Session at the American Society of Clinical Oncology (ASCO) ...

Vera Therapeutics, Inc.’s VERA share price has surged by 6.17%, which has investors questioning if this is right time to sell.

STATEN ISLAND, N.Y. -- While the Seaview Avenue redesign — officially unveiled by the city earlier this month — was met with ...

Nail fungus can be a persistent and distressing condition, affecting both the aesthetic appeal of your nails and your overall ...

Protagonist Therapeutics, Inc.’s PTGX share price has surged by 6.71%, which has investors questioning if this is right time to sell.

Highlights,Wellington Management Group LLP reduced its holdings in Vera Therapeutics during the fourth quarter.,Schroder Investment Management and Pictet Asset Management increased their equity ...

BOSTON -- Patients with focal segmental glomerulosclerosis (FSGS) achieved some degree of proteinuria remission more often ...

A post-hoc analysis of the DUPLEX trial shows significantly greater improvements in proteinuria-related outcomes vs irbesartan for tough-to-treat FSGS.

You’ve viewed 1 of 5 articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.